Blocking T-cell costimulation in transplantation: Opportunities and challenges

Transfusion

Volumn 40, Issue 2, 2000, Pages 139-142

  Xian Chang Li, ^a   Strom, T B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD40 ANTIGEN; CYCLOSPORIN A; GROWTH FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2; TACROLIMUS;

ALLOGRAFT; APOPTOSIS; CELL STIMULATION; CELL TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; GRAFT REJECTION; GRAFT SURVIVAL; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION;

EID: 0033956536     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40020139.x     Document Type: Editorial

References (28)

1. 1 Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994 ; 76: 275–85.
2. 2 Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990 ; 248: 1349–56.
3. 3 Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl‐XL. Immunity 1995 ; 3: 87–98.
4. 4 Linsley PS, Greene JL, Brady W, et al. Human B7‐1 and B7‐2 bind with similar activities but distinct kinetics to CD28 and CTLA‐4 receptors. Immunity 1994 ; 1: 793–801.
5. 5 Bluestone JA. Is CTLA‐4 a master switch for peripheral T cell tolerance? J Immunol 1997 ; 158: 1989–93.
6. 6 Krummel MF, Allison JP. CD28 and CTLA‐4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995 ; 182: 459–65.
7. 7 Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in ctla‐4. Science 1995 ; 270: 985–8.
8. 8 Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA‐4 T cell activation molecule. Science 1992 ; 257: 792–5.
9. 9 Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long term survival of xenogeneic pancreatic islet grafts induced by CTLA‐41g. Science 1992 ; 257: 789–92.
10. 10 Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996 ; 14: 233–58.
11. 11 Sayegh MH. Finally, CTLA 41g graduates to the clinic. J Clin Invest 1999 ; 103: 1223–5.
12. 12 Kirk AD, Harlan DM, Armstrong NN, et al. CTLA‐41g and anti‐CD40L ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997 ; 94: 8789–94.
13. 13 Perez VL, Parijs LV, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA‐4 engagement. Immunity 1997 ; 6: 411–7.
14. 14 Zheng XX, Markees TG, Hancock WW, et al. CTLA‐4 signals are required to optimally induce allograft tolerance with combined donor specific transfusion and anti‐CD154 monoclonal antibody treatment. Immunology 1999 ; 162: 4983–90.
15. 15 Markees TG, Phillips NE, Gordon EJ, et al. Long term survival of skin allografts induced by donor splenocytes and anti‐CD154 antibody in thymectomized mice requires CD4+ T cells, interferon gamma (IFN‐g), and CTLA4. J Clin Invest 1998 ; 101: 2446–55.
16. 16 Judge TA, Wu Z, Zheng XG, et al. The role of CD80, CD86, and CTLA‐4 in alloimmune responses and the induction of long term allograft survival. Immunology 1999 ; 162: 1947–51.
17. 17 Grewal IS, Flavell RA. CD40 and CD154 in cell mediated immunity. Annu Rev Immunol 1998 ; 16: 111–35.
18. 18 Yang Y, Wilson JM. CD40 ligand‐dependent T cell activation: requirement of B7‐CD28 signaling through CD40. Science 1996 ; 273: 1862–4.
19. 19 Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997 ; 9: 641–7.
20. 20 Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal anfibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999 ; 5: 686–93.
21. 21 Larsen CP, Elwood ET, Alexander DZ, et al. Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996 ; 381: 434–8.
22. 22 Bachmann MF, Wong BR, Josien R, et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand independent T helper cell activation. J Exp Med 1999 ; 189: 1025–31.
23. 23 Green EA, Flavell RA. TRANCE‐RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med 1999 ; 189: 1017–20.
24. 24 Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homologue of B7.1 and B7.2, is induced by TNF‐α. Immunity 1999 ; 11: 423–32.
25. 25 Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998 ; 10: 518–24.
26. 26 Newell KA, He G, Guo Z, et al. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allo‐graft rejection mediated by CD4+ but not CD8+ T cells. Immunology 1999 ; 163: 2358–62.
27. 27 Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. Immunology 1999 ; 163: 4805–10.
28. 28 Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999 ; 5: 1298–302.